Hyperfine expects 2026 revenue of $20 mln to $22 mln, unchanged from prior outlook
Company maintains 2026 cash burn guidance at $26 mln to $28 mln
Overview
US portable MRI maker's Q2 revenue grew 45% yr/yr but missed analyst expectations
Net loss for Q2 widened slightly to $9.3 mln, loss per share was $0.09
Company maintained full-year guidance, expecting 55% revenue growth and lower cash burn
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Miss
$3.9 mln
$4.14 mln (3 Analysts)
Q2 Loss Per Share
$0.09
Q2 Net Loss
$9.3 mln
Q2 Operating Expenses
$10.45 mln
Q2 Operating Income
-$8.47 mln
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Hyperfine Inc is $2.00, about 104.1% above its August 5 closing price of $0.98
HYPR•
